D.E. Shaw & Co
KYTX icon

D.E. Shaw & Co’s Kyverna Therapeutics KYTX Stock Holding History

D.E. Shaw & Co’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.23M Buy
721,581
+203,069
+39% +$1.69M ﹤0.01% 2015
2025
Q4 		$4.87M Buy
+518,512
New +$3.85M ﹤0.01% 2318

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

D.E. Shaw & Co's KYTX Position: Q1 2026 in Review

D.E. Shaw & Co increased its Kyverna Therapeutics (KYTX) stake by 39% in Q1 2026, buying an estimated $1.69M and bringing the position to 721,581 shares worth $6.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2015.

D.E. Shaw & Co first reported a position in KYTX in Q4 2025 and has held it in 2 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • D.E. Shaw & Co held 721,581 shares of Kyverna Therapeutics worth $6.23M as of Q1 2026.
  • D.E. Shaw & Co bought 203,069 Kyverna Therapeutics shares in Q1 2026, an estimated $1.69M.
  • Kyverna Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2015 holding.
  • D.E. Shaw & Co first reported a position in Kyverna Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.